Company
GBS Inc.
Headquarters: New York, NY, United States
Employees: 7
CEO: Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D.
Market Cap
$4.8 Million
USD as of Jan. 1, 2024
GBS Inc. Categories
United States Healthcare Medical DevicesUnited States Healthcare United States Medical Devices
Top Competitors by Market Capitalization
Industry: Medical Devices
| Company | Market Cap (USD) |
|---|---|
| Abbott | $192.67 B |
| Stryker Corporation | $113.24 B |
| Medtronic | $111.60 B |
| Boston Scientific Corporation | $85.22 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
GBS Inc. has the following listings and related stock indices.
Stock: NASDAQ: GBS wb_incandescent